Pfizer starts production at $50M plant in Saudi Arabia

Pfizer is starting production at a new $50 million plant in Saudi Arabia.

The Middle East is seen as one of the emerging markets that offer drugmakers better-than-average returns. Pfizer, which was one of the first to act on that opportunity, has now officially opened a plant in Saudi Arabia that it began planning more than 5 years ago.

The $50 million, 11,108 square meter (119,565 square foot) manufacturing and packaging facility is slated to begin production on 16 products, according to a release provided by Pfizer and published in the Saudi Gazette. Those drugs include cardiovascular, pain, anti-infective, urology and neurology products.

The plant is in King Abdullah Economic City (KAEC) on the west coast of the Red Sea, north of Jeddah. It will employ about 125 people, half of them Saudi nationals. Pfizer began discussions on the plant in 2011.

Cambrex Webinar

Understanding the Importance of Crystallization Processes to Avoid Unnecessary Cost, Risk and Development Delays

Wednesday, May 27, 2020 | 10am ET / 7am PT

A well-developed crystallization process can produce suitable particles that can facilitate consistent filtration, drying and formulation of the API and allow confident and reliable manufacturing of the final drug product, while avoiding unnecessary cost, risk and development delays.

“This facility... allows us to develop local manufacturing expertise and capabilities to help meet our shared commitment with the government to provide a continued reliable supply of innovative and essential medicines for patients in Saudi Arabia,” Hussein El Hakim, country manager for Pfizer Saudi Limited, said in a statement.  

The plant is not Pfizer’s only effort to sell in the country. The U.S. drugmaker in 2014 struck a deal with Tabuk Pharmaceuticals that gave the Saudi-based company exclusive rights to manufacture and sell in the kingdom "second brand" versions of four Pfizer drugs.

Saudi Arabia has created incentives to attract pharma manufacturing and a host of foreign companies, including AbbVie, Boehringer Ingelheim and Cipla, have projects underway in the country.

Suggested Articles

The eight-year deal will initially cover lupus drug Benlysta and could expand to other GSK specialty-care products in the future.

With a new £131 million contribution from the U.K. government, VMIC aims to both speed up and expand on its prior ambitions.

Pricing controversies shouldn't overshadow Phlow's promise to provide low-cost drugs to address COVID-19, says the CEO of partner Civica Rx.